GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity

On September 3, HUTCHMED (China) Limited (NASDAQ:HCM%20ltd/1648257/)) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers.
Read more...